key: cord-0786919-0bh43uzy authors: Valdivia, A.; Torres, I.; Latorre, V.; Frances-Gomez, C.; Albert, E.; Gozalbo, R.; Alcaraz, M. J.; Buesa, J.; Rodriguez-Diaz, J.; Geller, R.; Navarro, D. title: Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays date: 2020-09-09 journal: nan DOI: 10.1101/2020.09.07.20188151 sha: 96cea056215dfb432f033c7bd3e63da2061da9d5 doc_id: 786919 cord_uid: 0bh43uzy Background: Whether antibody levels measured by commercially-available enzyme or chemiluminescent immunoassays targeting the SARS-CoV-2 spike (S) protein can act as a proxy for serum neutralizing activity remains to be established for many of these assays. Objectives: To evaluate the degree of correlation between neutralizing antibodies (NtAb) binding the SARS-CoV-2 Spike (S) protein and SARS-CoV-2-S-IgG levels measured by four commercial immunoassays in sera drawn from hospitalized COVID-19 patients. Patients and Methods: Ninety sera from 51 hospitalized COVID-19 patients were assayed by a pseudotyped virus neutralization assay, the LIAISON SARS-CoV-2 S1/S2 IgG, the Euroimmun SARS-CoV-2 IgG ELISA, the MAGLUMI 2019-nCoV IgG and the COVID-19 ELISA IgG assays. Results: Overall, the results obtained with the COVID-19 ELISA IgG test showed the highest agreement with the NtAb assay ({kappa}, 0.85; 95% CI, 0.63-1). The most sensitive tests were the pseudotyped virus NtAb assay and the COVID-19 ELISA IgG assay (92.2% for both). Overall, the degree correlation between antibody titers resulting in 50% virus neutralization (NtAb50) in the pseudotyped virus assay and SARS-CoV-2 IgG levels was strong for the Euroimmun SARS-CoV-2 IgG ELISA (Rho=0.73) and moderate for the remaining assays (Rho=0.48 to 0.59). The kinetic profile of serum NtAb50 titers could not be reliably predicted by any of the SARS-CoV-2 IgG immunoassays. Conclusions: the suitability of SARS-CoV-2-S-IgG commercial immunoassays for inferring neutralizing activity of sera from hospitalized COVID-19 patients varies widely across tests and is influenced by the time of sera collection after the onset of symptoms. Test performances were evaluated for their sensitivity with the associated 95% 1 3 3 confidence interval (CI). Cohen's Kappa (κ) statistic was used to evaluate the 1 3 4 qualitative agreement between immunoassays. Spearman's rank test was used to assess 1 3 5 the correlation between continuous variables using the entire dataset. To identify the 1 3 6 optimal SARS-CoV-2 IgG levels measured by commercial immunoassays predicting 1 3 7 NtAb 50 titers ≥ 1/160, receiver operating characteristic (ROC) curve analysis was performed. Two-sided exact P-values are reported, and a P-value <0.05 is considered 1 3 9 statistically significant. The analyses were performed using SPSS version 20.0 (SPSS, 1 4 0 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 9, 2020. . https: //doi.org/10.1101 //doi.org/10. /2020 Chicago, IL, USA). Kinetics of antibody titers/levels were categorized as ascendant (an Qualitative results returned by immunoassays were evaluated either considering the 1 5 3 entire data set or grouping sera according to the time of sampling after the onset of 1 5 4 symptoms (<15 days or ≥ 15 days) ( Table 2 ). As shown in Table 3 , overall, results 1 5 5 provided by the COVID-19 ELISA IgG test best matched those obtained with the NtAb 1 5 6 assay (κ, 0.84; 95% CI, 0.63-1), followed by those of the Euroimmun SARS-CoV-2 IgG 1 5 7 ELISA (κ, 0.52; 0.52; 95% CI, 0.22-0.81), LIAISON SARS-CoV-2 S1/S2 IgG (κ, 0.5; trend was observed when sera collected either < 15 days or ≥ 15 days after the onset of 1 6 0 symptoms were analyzed separately. Notably, the concordance between results returned 1 6 1 by the NtAb assay and the COVID-19 ELISA IgG was 100% for sera obtained at ≥ 15 1 6 2 days following symptom onset. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.07.20188151 doi: medRxiv preprint Overall, the most sensitive tests were the GFP reporter-based pseudotyped virus 1 6 5 neutralization assay and the COVID-19 ELISA IgG, followed by the MAGLUMI 2019-1 6 6 nCoV IgG, the Euroimmun SARS-CoV-2 IgG ELISA and the LIAISON SARS-CoV-2 1 6 7 S1/S2 IgG (Table 4 ). Differences in sensitivity were more apparent when sera were 1 6 8 collected early after the onset of symptoms (< 15 days) were analyzed independently, and these tended to decrease in sera obtained at a later time point (Table 4 ). LIAISON SARS-CoV-2 S1/S2 IgG threshold, with minimal differences across the LIAISON SARS-CoV-2 S1/S2 IgG [12, 13, 15, [18] [19] [20] , but not, to the best of our 2 1 6 knowledge, for the MAGLUMI 2019-nCoV IgG and COVID-19 ELISA IgG assays. It 2 1 7 must be highlighted that antibody titers measured by the NtAb assay used in the current 2 1 8 study strongly correlate with those quantitated by assays using wild type SARS-CoV-2 2 1 9 [26]. Here, the overall agreement between qualitative (positive/negative) results returned by 2 2 1 the NtAb assay and the four commercially-available immunoassays was fairly good, 2 2 2 ranging from 97% for the COVID-19 ELISA IgG assay to 88% for LIAISON SARS- CoV-2 S1/S2 IgG and MAGLUMI 2019-nCoV IgG assays. Concordance across results immunoassays. As previously reported, the sensitivity of all immunoassays increased 2 3 0 after the second week following the onset of symptoms [12, 13, 15, 16, 18, 19, 20] . The 2 3 1 overall degree of correlation between NtAb 50 antibody titers and SARS-CoV-2 IgG 1 1 against S1, which contains the RBD domain and concentrates immunodominant 2 3 5 epitopes eliciting high-affinity NtAb antibodies [3, 5, 21, 22] may account for this 2 3 6 finding. IgG antibodies lacking neutralizing activity and recognizing epitopes within S2 2 3 7 and N proteins (additional targets in the remaining immunoassays) may compete with 2 3 8 those binding S1, thus decreasing the degree of correlation. Interestingly, in all cases, 2 3 9 correlations were better for sera collected early after the onset of symptoms than for for all immunoassays, although sensitivities were overall poor. In the absence of a reference panel of sera with standard levels of NtAb antibodies, 2. Nat Rev Immunol 2020; 20:392-394. Potently neutralizing and protective human antibodies against SARS-CoV-2. Identifies S1/S2 Neutralizing IgG In COVID-19 Patients Semiquantitatively. J All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 9, 2020. . Tumor 3 (6) Total lymphocyte count (*10 9 /L) 1.15 (0.17-3.98) a measurements in sera used for serological analyses reported in the current study. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 9, 2020. . A total of 90 sera were included, of which 41 were collected <15 days after the onset of symptoms and 49 afterwards (≥15 days). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 9, 2020. . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 9, 2020. . A total of 90 sera were included, of which 41 were collected <15 days after the onset of symptoms and 49 afterwards (≥15 days). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.07.20188151 doi: medRxiv preprint /ml) Lactose dehydrogenase (U/l)